GlassScriptPhysician profile
Naing T Kyaw
NPI 1689784308
$13,645.15
in general payments reported to CMS, 2019-2025
18 companies · $8,456 in 2025
The $8,456 reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $240 · 2021: $234 · 2022: $241 · 2023: $17.18 · 2024: $4,210 · 2025: $8,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,301 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,400 · Consulting Fee: $2,400 · Food and Beverage: $1,527 · Education: $54.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,301.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,400.00 |
| Consulting Fee | $2,400.00 |
| Food and Beverage | $1,527.43 |
| Education | $54.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $12,618.49 | 2019-2025 | Optiflux, Korsuva, Velphoro |
| Vifor Pharma, INC. | $198.62 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $164.19 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $144.68 | 2019-2022 | |
| Akebia Therapeutics INC | $89.14 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $81.10 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $49.24 | 2022 | |
| Amgen INC. | $42.21 | 2019 | |
| Travere Therapeutics, INC. | $33.78 | 2024 | |
| Nxstage Medical, INC. | $33.49 | 2024 | |
| Mallinckrodt Hospital Products INC. | $29.40 | 2020 | |
| Glaxosmithkline, LLC. | $27.90 | 2021-2022 | |
| Recor Medical INC | $25.71 | 2024 | Paradise Renal Denervation System |
| Bayer Healthcare Pharmaceuticals INC. | $24.47 | 2022 | |
| Mallinckrodt Enterprises LLC | $22.16 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $22.02 | 2019 | |
| Aurinia Pharma U.S., INC. | $20.17 | 2021 | |
| Daiichi Sankyo INC. | $18.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naing Kyaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.